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The Evolution of Therapy for Single Vessel Disease:
A Treatment Comparison of Medicine, Angioplasty
and Left Internal Mammary Artery Graft for Proximal
Left Anterior Descending Disease
Joseph A. Puma, Michael H. Sketch, Jr., Laura H. Gardner, Charlotte L. Nelson,
Harry R. Phillips, Richard S. Stack, Robert M. Califf. Duke University Medical Cente"
Durham. N. C.
coronary artery disease (CAD) and good left ventricular function is unclear. To
address this issue, we retrospectively analyzed 400 matched pts with three
vessel CAD and ejection fraction >40% who underwent either elective an-
gioplasty (PTCA) or bypass surgery (CABGJ. Exclusion criteria included prior
PTCA or CABG, left main CAD, evolving myocardial infarction, and chronic
total occlusions. The groups were matched for age, ejection fraction (59%
= PTCA vs 57% = CABG) and extent of CAD. Long-term follow-up was avail-
able in all pts and averaged 58 ± 25 months.
Events Medicine PTCA LIMA P-value
- unadjusted survival (%) 78 85 91 0.001
- adjusted survival (%) 84 86 90 0.24
- event-free survival (%) 54 43 72 0.0001
Conclusion: There is a trend towards improved long-term survival in prox-
imal LAD disease with a strategy of revascularization, particularly the LIMA
graft. Furthermore, event-free survival is significantly improved with the LIMA
graft as compared to medical therapy or PTCA.
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None of these comparisons is statistically significant.
Correlation Analysis·Significant Findings
Xue-Qiao Zhao, B. Greg Brown, Lynn A. Hillger, HUlman X. Barnhart, Spencer
B. King III. EASTAngiographic Core Lab, Univ. of Washington. Seattle. WA: Emory Uni~
School of Medicine. ANanta, GA
The Emory Angioplasty vs. Surgery Trial (EAST) randomized pts with multi-
vessel disease to an initial strategy of PTCA or CABG. Of 298 pts who com-
pleted 3-year angiographic follow-up (FlU). 53 (18%) had at least one new
lesion (N-Les) in their native vessels. The definitions for N-Les were: (1) per-
cent stenosis (%5) at baseline was <50%5. measured by quantitative arteri-
ography, (2) increased by at least 10%5 to become ::::50%5 during the 3-year
FlU. N-Les were located either in a non-procedure native vessel (Tp. A) or in
procedure vessel, distal to the direct effects of PTCA or CABG (Tp. B). "In-
strumented" N-Les possibly due to balloon injury and "hemdynamic" N-Les
proximal to, or at, the CABG sites were excluded from this analysis. PTCA
and CABG were compared in terms of proportion of pts with N-Les (any. Tp. A
or Tp. B) or whose N-Les caused O-wave infarction (MI), or a large reversible
thallium defect (TL). or required additional procedure(s) (AddP). and of %5 of
these N-Les at baseline (%SB) and when N-Les were first seen (%SN-Les).
The occurrence of N-Les, per pt, was correlated with 30 common risk vari-
ables.
Results:
Comparison of Frequency of N-Les between PTCA and CABG
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Conclusion: In pts with three vessel CAD and ejection fractions above
40%, PTCA and CABG resulted in equivalent long-term survival and freedom
from death andlor myocardial infarction. However, recurrent revasculariza-
tion procedures were required much more frequently following PTCA.
9:30
Conclusions: There were no differences between PTCA and CABG in terms
of the frequency of N-Les, and the frequency of ischemic evidence due to
N-Les over the 3 years. Of 136 pts who completed 3-year angiographic FlU
and had MI or TL or AddP. only 19 (14%) were due to N-Les. As expected,
both PTCA and CABG pts with atherogenic risk profiles were more likely to
develop N-Les.
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Saphenous vein bypass grafting for single vessel disease offers no survival
or symptom relief advantage compared to medical therapy. Recent evidence
suggests the use of the internal mammary artery or PTCA may be more bene-
ficial than medicine. To examine the outcome of these treatment strategies, a
retrospective analysis of prospectively collected data on 23,018 consecutive
patients undergoing cardiac catheterization between April 1986 and Febru-
ary 1994 was performed. Of the 6,432 patients with single vessel disease,
1,222 had a proximal left anterior descending (LAD) stenosis> 74% and no
prior PTCA or CABG. A total of 289 were managed medically, 760 underwent
PTCA, and 172 received a left internal mammary artery (LIMA) graft.
Baseline demographic data and risk factor profiles were similar except for
a higher incidence of diabetes (19 vs 15 vs 11 %), history of MI (72 vs 58
vs 48%) CHF (18 vs 7 vs 8%). and total occlusions (44 vs 17 vs 7%) and
lower incidence of unstable angina (40 vs 61 vs 64%) in the medical group
as compared to PTCA and LIMA graft. respectively.
Kaplan-Meier 6-year estimates:
Joseph A. Puma, Michael H. Sketch, Jr., James E. Tcheng, Laura H. Gardner,
Charlotte L. Nelson, Donald F. Fortin, Harry R. Phillips, Richard S. Stack, Robert
M. Califf. Duke University Medical Cente" Durham, N.c.
While medical management of pts with single vessel chronic total occlusions
has been associated with high rates of death, MI and need for revasculariza-
tion at long-term follow-up, the role of PTCA in these pts is poorly defined.
To develop a paradigm for the comparison of medical therapy versus PTCA
in the management of chronic total occlusions, we retrospectively analyzed
prospectively-collected data on 23,005 pts undergoing cardiac catherization
between April 1986 and February 1994. Of the 6,430 pts with single-vessel
disease, 748 had a total occlusion without an acute myocardial infarction
within 30 days and no history of PTCA or CABG. A total of 611 pts were
managed medically and 137 pts underwent PTCA.
The 2 groups were similar with regard to most baseline characteristics, but
the medically-treated group had higher rates of CHF (16 vs 9%) and prior MI
(50 vs 31 %), and the PTCA cohort had more unstable angina (36 vs 20%) and
left anterior decending disease (63 vs 34%). While early mortality was simi-
lar, the 4-year mortality was statistically insignificantly higher in the medical
cohort (12 vs 7%).
Kaplan-Meier 4-year estimates:
9:00
Long-term Survival with a Chronic Total Coronary
Occlusion: A Comparison of Medical Therapy versus
Angloplasty in Patients with Single Vessel Disease
Events
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Conclusion: The trend towards lower mortality in the presence of higher
non-fatal events provides a rationale for opening chronic total occlusions that
can be tested in larger prospective studies.
1738-61 Recanalization of Chronically Occluded Bypass
Grafts: The Effect of Angioplasty Site Following
Extended Urokinase Infusion on 6 Month Patency
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Coronary Angioplasty versus Bypass Surgery for
Patients with Three Vessel Coronary Disease and
Ejection Fraction >40%
Siroth Charnond, James H. O'Keefe, Jr., Ben D. McCallister. Mid America Heart
Institute. f(J)nsas City, Missoud
The optimal mode of revascularization for patients (pts) with three vessel
Joseph R. Hartmann, Louis S. McKeever, William W. O'Neill, Christopher J. White,
Patrick J. Whitlow, Elaine L. Enger, ROBUST Investigators. USA
One hundred seven patients with chronically occluded aortocoronary bypass
grafts were enrolled in the ROBUST trial to determine the safety and effi-
cacyof low dose, long-term urokinase intracoronary infusions in recanalizing
these vessels. Initial patency rate was 69% and 6 month patency was 47%.
The relationship between site of angioplasty following successful lysis and
6 month graft patency was reviewed. Patients with angioplasty at the distal
anastomosis had an 88% acute patency rate vs 85% at sites within the graft.
